Prostate cancer is one of the most common malignant tumors among men and has ranked among the leading cancers in Taiwan in recent years. With an aging population and increasing awareness of early detection, achieving accurate diagnosis at an early stage has become a critical challenge for clinicians and the medical community.
Against this backdrop, the advancement of PSMA PET imaging technology has brought revolutionary progress in prostate cancer diagnosis. This technology enables the detection of lesions with high sensitivity and specificity, allowing physicians to identify even small metastatic sites at an early stage. It also assists clinicians in precisely determining disease stages, providing stronger diagnostic support for treatment decision-making.
Furthermore, the integration of nuclear medicine imaging and biomarkers has ushered prostate cancer diagnostics toward greater precision and comprehensiveness. This interdisciplinary approach enhances the accuracy of disease staging and risk assessment while laying the foundation for developing personalized clinical treatment strategies.
To promote the clinical implementation of precision medicine, Primo sincerely invites specialists and physicians in urology, nuclear medicine, and pathology to participate in the upcoming symposium:
“Advances in Precision Diagnosis for Suspected Prostate Cancer: A Comprehensive Perspective on PSMA PET Imaging and Biomarkers.”
This symposium will explore key topics including:
🔹 Clinical breakthroughs of PSMA PET imaging in early diagnosis and metastasis detection
🔹 The applications and future development of nuclear medicine in prostate cancer diagnosis and treatment
🔹 Building a more precise diagnostic and therapeutic model for prostate cancer
🔹 Continuing Education Credits: Urology (1.5 points)
Registration Link: https://reurl.cc/oYaXrQ
📅 Date｜Saturday, November 8, 2025, 13:30~17:30
📍 Venue｜Grand Hilai Taipei, 6th Floor Conference Center
We sincerely welcome medical professionals from hospitals and medical societies to join us in discussing the latest trends and clinical practices in prostate cancer diagnosis, and to work together in advancing precision medicine in Taiwan.
